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Neuroblastoma cells depend on HDAC11 for mitotic cell
cycle progression and survival
Theresa M Thole1,2,3, Marco Lodrini1,3, Johannes Fabian3,11, Jasmin Wuenschel1,3, Sebastian Pfeil1, Thomas Hielscher4,
Annette Kopp-Schneider4, Ulrike Heinicke5, Simone Fulda5,6,7, Olaf Witt2,3, Angelika Eggert1, Matthias Fischer8,9 and
Hedwig E Deubzer*,1,2,3,10
The number of long-term survivors of high-risk neuroblastoma remains discouraging, with 10-year survival as low as 20%, despite
decades of considerable international efforts to improve outcome. Major obstacles remain and include managing resistance to
induction therapy, which causes tumor progression and early death in high-risk patients, and managing chemotherapy-resistant
relapses, which can occur years after the initial diagnosis. Identifying and validating novel therapeutic targets is essential to
improve treatment. Delineating and deciphering specific functions of single histone deacetylases in neuroblastoma may support
development of targeted acetylome-modifying therapeutics for patients with molecularly defined high-risk neuroblastoma profiles.
We show here that HDAC11 depletion in MYCN-driven neuroblastoma cell lines strongly induces cell death, mostly mediated by
apoptotic programs. Genes necessary for mitotic cell cycle progression and cell division were most prominently enriched in at
least two of three time points in whole-genome expression data combined from two cell systems, and all nine genes in these
functional categories were strongly repressed, including CENPA, KIF14, KIF23 and RACGAP1. Enforced expression of one selected
candidate, RACGAP1, partially rescued the induction of apoptosis caused by HDAC11 depletion. High-level expression of all nine
genes in primary neuroblastomas significantly correlated with unfavorable overall and event-free survival in patients, suggesting a
role in mediating the more aggressive biological and clinical phenotype of these tumors. Our study identified a group of cell cycle-
promoting genes regulated by HDAC11, being both predictors of unfavorable patient outcome and essential for tumor cell viability.
The data indicate a significant role of HDAC11 for mitotic cell cycle progression and survival of MYCN-amplified neuroblastoma
cells, and suggests that HDAC11 could be a valuable drug target.
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Neuroblastoma, a neuroectodermally derived embryonic
tumor and most common extracranial tumor of childhood,
remains a major cause of cancer-related deaths in children,
mostly due to systemic and resistant relapses.1 MYCN
oncogene amplifications,2,3 TERT activation by genomic
rearrangements,4,5 ATRX loss-of-function mutations/deletions6
and germline/somatic activating ALK mutations7–10 define
patient subgroups at high risk for failing primary long-term
remission despite aggressive multimodal treatment. Treatment
for relapsed neuroblastoma and even first-line therapy for
molecularly defined high-risk disease is currently undergoing a
paradigm shift from classical cytotoxic agent combinations
toward incorporating targeted drugs and immunothera-
peutics into treatment schedules. Developing how and when
to combine these newer precise therapeutics with established
treatment elements such as classical chemotherapy is
challenging.
Drugs currently under clinical investigation for relapsed/
refractory neuroblastoma patients include the mTOR
inhibitor, rapamycin (NCT01467986), and the ALK inhibitors,
crizotinib (NCT00939770, NCT02559778, NCT01606878,
NCT02034981) and LDK378 (NCT01742286). The strong
anti-tumoral activities of inhibitors for HDAC family members,
AURKA, BET/bromodomain-containing proteins, MDM2,
MAP2K1 (formerly MEK) and CDK4/6 observed in preclinical
neuroblastoma models11–16 suggest that further drugs will
enter pediatric phase I testing in the near future. Inhibitors of
class I or all classical histone deacetylases that are currently
approved or being evaluated in clinical cancer trials in adults17
give rise to mostly hematological dose-limiting toxicities,
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presumably due to the inhibition of several family members.
This could potentially be overcome by selective blockade of
single HDAC family members.
Further advances in understanding the role of single histone
deacetylases are a prerequisite to fully exploiting the level of
plasticity that can be therapeutically addressed with this class
of acetylome-modifying drugs. MYCN was shown to recruit
HDAC1/2/3/5 to promoter sites to repress transcription in
neuroblastoma cells,18–21 whereasHDAC8andHDAC10 inhibit
differentiation and promote autophagy-mediated survival in a
MYCN-independent manner.22,23 Gao et al.24 identified and
characterized HDAC11 in 2002, the only class IV HDAC family
member identified to date, which is located within the ~25 kb
region of chromosome 3p25.1. Expression of the FLAG-tagged
347 amino acid open reading frame in human embryonic kidney
293 cells, demonstrated the protein primarily localizes to the
nucleus and is capable of deacetylating a synthetic peptide
derived from histone H4.24 Subsequent studies in recent years
have shed light on the role of HDAC11 in health and disease.25
Here we aimed to assess the significance of HDAC11
expression for neuroblastoma biology, which is as yet unknown.
We recently showed that HDAC11 plays an important role in
controlling proliferation in several carcinoma cell lines.26 BE(2)-
C and IMR-32 were chosen as representative cell lines for the
high-risk neuroblastoma subtype characterized by MYCN
amplification and loss of heterozygosity at chromosome 1p.
The BE(2)-C cell line, established from a bone marrow
metastasis after the patient had received 5 months of
polychemotherapy,27 is hemizygous for TP53, with the remain-
ing allele harboring a missense mutation at codon 135 that
renders TP53 non-function and the cell line resistance to
doxorubicin.28 IMR-32 cells harbor a partial ALK amplification,
resulting in constitutive ALK activity leading to uncontrolled
proliferation.29We assessed the effect of HDAC11 depletion on
phenotype in these two neuroblastoma cell models and
performed whole-genome expression profiling to decipher the
pathways triggering the HDAC11 depletion phenotype in
neuroblastoma cells.
Results
HDAC11 depletion in neuroblastoma cells triggers cell
death preceded by aberrant mitotic spindle assemblies.
To decipher mechanisms controlled by HDAC11 in neuro-
blastoma cells, we assessed phenotypic appearance, intra-
cellular adenosine triphosphate (ATP) content, and number of
viable and dead cells following transient HDAC11 knockdown
in BE(2)-C and IMR-32 cells. Two different siRNAs directed
against HDAC11 (Supplementary Table S1) were used to
Figure 1 HDAC11 depletion in neuroblastoma cells causes aberrant mitosis and cell death. (a) Phase contrast microscopy pictures showing the phenotype of BE(2)-C and
IMR-32 neuroblastoma cells 96 h after transfection with HDAC11- or negative control siRNA. Original magnification × 200. (b) Intracellular ATP content of BE(2)-C and IMR-32
cultures 96 h after transfection with HDAC11- or negative control siRNAs (mean fold change over mock-transfected cells± S.D. is shown, n= 3). (c and d) Viable and dead BE
(2)-C and IMR-32 cell count using a semi-automatic VI-CELL Cell Viability Analyzer 96 h after transfection with HDAC11- or negative control siRNAs. Mean fold change over
viable mock-transfected cells± S.D. is shown in (c), n⩾ 3. Mean percentage of dead cells is shown in d, n⩾ 3. (e) Fluorescent microscopic and confocal images of DAPI-stained
DNA in BE(2)-C and IMR-32 cells transfected with HDAC11- or negative control siRNA for 48 h. DAPI-stained cells were analyzed using the × 20 objective on a conventional
widefield microscope and the × 63 objective on a confocal microscope. Arrowheads indicate aberrantly constituted mitotic spindle assemblies. (f) Quantification of the fluorescent
microscopic images shown in e. At least 10 microscopic fields were evaluated per treatment group by two experimenters. (g) Western blot analysis of phospho Histone H3 (Ser10)
expression 48 h after transfection of HDAC11- or negative control siRNA. Histone H3 served as loading control. *Po0.05; **P⩽ 0.01; ***P⩽ 0.001
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control unspecific and off-target effects. HDAC11 expression
was reduced up to 95% on the mRNA level, as measured by
qRT-PCR (Supplementary Table S2; Supplementary Figures
S1a–b), and up to 85% on the protein level related by western
blotting (Supplementary Figures S1c–d). Cell culture density
was reduced by HDAC11 depletion, and detached single
cells and clusters floated in the culture medium 96 h after
transfection (Figure 1a), suggesting proliferative inhibition
and cell death induction. Intracellular ATP content was
quantified 96 h after transfection by the CellTiter-Glo assay.
HDAC11 depletion diminished ATP content in BE(2)-C and
IMR-32 cells by 59–93%, compared to cells transfected with
negative controls (Figure 1b), indicating that loss of HDAC11
activity reduced metabolic activity. Consistent with this
finding, semi-automated cell viability analysis based on
trypan blue exclusion revealed a 63–86% reduction in the
number of membrane-intact viable BE(2)-C or IMR-32 cells
96 h after HDAC11 depletion (Figure 1c), whereas the
number of membrane-permeable dead cells increased by
1.8- to 4.5-fold (Figure 1d). Transient HDAC11 knockdown in
the SH-SY5Y and SK-N-AS neuroblastoma cell lines, which
lackMYCN amplification, diminished ATP content by 21–38%
(Supplementary Figures S2a–b). Semi-automated analyses
detected a 32–45% reduction in the number of viable
SH-SY5Y or SK-N-AS cells 96 h after HDAC11 depletion
and a 1.3- to 1.7-fold increase in the number of dead cells
(Supplementary Figures S2c–d). We observed an apparent
increase in mitotic BE(2)-C and IMR-32 cells using fluor-
escent microscopy of diamidino-2-phenylindole (DAPI)-
stained adherently growing cells 48 h after HDAC11 depletion
and prior to time points assessing cell death (Figure 1e).
Quantifying the percentage of mitotic cells per microscopic
field showed HDAC11 depletion increased mitotic BE(2)-C
cells from 5% to 22–47% and mitotic IMR-32 cells from 4% to
12–16% (Figure 1f). Confocal microscopy of the DAPI-
stained cells revealed aberrantly constituted mitotic spindle
assemblies in HDAC11-depleted cells while negative controls
harbored normal appearing mitotic spindle assemblies
(Figure 1e). Ser10 of histone H3 is phosphorylated in mitotic
cells, allowing direct quantification of mitotic cells. HDAC11
depletion increased phospho H3 (Ser10) levels by approxi-
mately three-fold in BE(2)-C and IMR-32 cells 48 h after
Figure 2 HDAC11 depletion in neuroblastoma cells triggers caspase activation and caspase-dependent apoptosis. (a and b) Caspase 3-like activity was measured in a
caspase 3-like activity assay in time course 24–96 h after transfection of BE(2)-C and 72–96 h after transfection of IMR-32 cells with HDAC11- or negative control siRNAs (mean
fold changes over mock±S.D., n= 3). (c and d) CASP3 and PARP cleavage was analyzed by western blotting 72–96 h after transfection of BE(2)-C (c) and IMR-32 cells (d) with
HDAC11- or negative control siRNAs. Shown are the full-length CASP3 (32 kDa) and poly (ADP-ribose) polymerase (PARP) proteins (116 kDa), and the active cleavage bands of
CASP3 (17, 12 kDa) and PARP (89 kDa). GAPDH served as a loading control. (e and f) Early- and late-stage apoptosis was determined by staining of annexin V shifted to the
outer plasma membrane 72 h after siRNA transfection (e; mean±S.D., n⩾ 5) and by quantifying DNA fragmentation in propidium iodide-stained nuclei at 96 h (f; mean± S.D.,
n= 3). (g) BE(2)-C and IMR-32 cells were transfected with HDAC11- or negative control siRNAs and treated with 20 μM zVAD.fmk or solvent control for 96 h. Shown is the mean
percentage of dead cells±S.D. measured with a semi-automated VI-CELL Cell Viability Analyzer (n⩾ 3). (h and i) Comparison of caspase 3-like activity in BE(2)-C (h) and
IMR-32 cells (i) transfected for 72 h with HDAC11 siRNAs or siRNAs directed against the class I HDACs 1, 2, 3 or 8 (mean fold change over mock± S.D., n= 3). *Po0.05;
**P⩽ 0.01; ***P⩽ 0.001
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siRNA transfection (Figure 1g), supporting the increase in
mitotic cells observed microscopically. Fluorescence-
activated cell sorting (FACS) of propidium iodide-stained BE
(2)-C cells demonstrated an increase of cells in G2/M from 33
to 51% 48 h after HDAC11 depletion (Supplementary Figures
S3a–e). Our results in neuroblastoma cell lines with and
without MYCN amplifications collectively highlight the sig-
nificance of HDAC11 expression for cellular viability, particu-
larly in the presence of MYCN amplification. Taken together,
our experiments show that HDAC11 depletion in neuroblas-
toma cells causes formation of aberrant mitotic spindle
assemblies followed by increased cell death.
HDAC11 depletion in neuroblastoma cells induces
apoptosis. To test whether apoptosis was involved in the
phenotype observed, we conducted caspase 3-like activity
assays, PARP western blotting, quantification of cell surface
phosphatidylserine expression and DNA fragmentation by
FACS. The time–response kinetic investigating caspase
3-like activity 24–96 h after siRNA transfection in BE(2)-C
cells demonstrated that HDAC11 depletion elicited an ~ 10-
fold increase in caspase 3-like activity over negative controls
at 72 h, reaching 11- to 23-fold at 96 h (Figure 2a). Caspase
3-like activity in IMR-32 was elevated up to 3.5-fold above
negative controls (Figure 2b). Caspase 3 cleavage fragments
were detected in BE(2)-C and IMR-32 cells by western
blotting (Figures 2c and d). Caspase-mediated apoptosis
involves cleavage of numerous substrates including PARP1,
a nuclear enzyme involved in DNA repair. Western blotting
detected increased cleavage to the 89-kDa PARP1 fragment
72 and 96 h after HDAC11 depletion (Figures 2c and d). To
collect further evidence that HDAC11 depletion induces
apoptosis, we analyzed the shift of phosphatidylserine from
the inner to the outer plasma membrane leaflet during
apoptosis using annexin V staining. Outer surface localization
of phosphatidylserine increased by 1.6- to 3.5-fold in BE(2)-C
and IMR-32 cells 72 h after siRNA transfection for HDAC11
depletion (Figure 2e; Supplementary Figure S4a). The
percentage of cells with fragmented DNA (sub-G1 fraction)
was determined by FACS analysis of propidium iodide-
stained cells. HDAC11 depletion triggered a 2- to 3.2-fold
increase in sub-G1 BE(2)-C and IMR-32 cells, reaching up to
62% 96 h after transfection (Figure 2f; Supplementary
Figure S4b). To assess the contribution of apoptosis to the
phenotype mediated by HDAC11 depletion, we combined
treatment with the pan-caspase inhibitor, zVAD.fmk, with
transfection of HDAC11-directed or negative control siRNA,
then quantified the number of dead BE(2)-C and IMR-32 cells
by semi-automated trypan blue staining. Stable inhibition of
proteolysis by activated caspases substantially prevented cell
death induction by HDAC11 depletion in BE(2)-C and IMR-32
cells (Figure 2g). The dependence of cell death induction on
caspase activity, the confirmation of PARP1 cleavage, the
increased cell surface localization of phosphatidylserine and
the presence of DNA fragmentation in dead or dying cells
strongly support a major involvement of the apoptotic
machinery in the phenotype observed.
We compared the induction of caspase 3-like activity by
HDAC11 depletion in BE(2)-C cells with that achieved
by singly depleting HDAC1, HDAC2, HDAC3 or HDAC8
(Supplementary Figures 1e–h). While HDAC11 depletion
resulted in an ~10-fold increase in caspase 3-like activity
72 h after transfection (compare Figure 2a with Figure 2h),
caspase 3-like activity in BE(2)-C cells depleted for HDAC1,
HDAC2 or HDAC8 was below five-fold of the respective
controls and below 7.5-fold of controls for HDAC3-depleted
cells (Figure 2h). Likewise, HDAC11 depletion induced
caspase 3-like activity in IMR-32 cells more strongly than
singly depleting HDAC1, HDAC2, HDAC3 or HDAC8
(Figure 2i). The strength of induction of caspase 3-like activity
by HDAC11 depletion suggests that HDAC11 could be a
valuable drug target for selective inhibition in concert with
other targeted therapeutics.
HDAC11 influences genes involved in mitotic cell cycle
progression and cell division. To detect transcriptomic
changes by HDAC11 depletion in a time-resolved manner,
whole-genome expression profiles of BE(2)-C and IMR-32
cells were generated using Illumina Human Sentrix-12
BeadChip arrays 42, 48 and 54 h after transfection with the
two different siRNAs targeting HDAC11 or a negative control
(compare with Figures 1,2). In total, 259 genes were
regulated (120 up and 139 down) by HDAC11 depletion in
BE(2)-C, and 167 genes were regulated (57 up and 110
down) by HDAC11 depletion in IMR-32 cells (Supplementary
Information). Genes differentially expressed relative to con-
trols at two or more time points in both cell lines (Po0.05)
after HDAC11 depletion were included in gene ontology (GO)
analyses. This approach identified 20 enriched biological
process terms in BE(2)-C cells and 18 in IMR-32 cells, of
which six overlapped in both cell models (Figure 3). Biological
processes enriched in both cell lines included M-phase of
Figure 3 Schematic model showing an enrichment of biological function terms
associated with cell cycle and cell division in a GO analysis of whole-genome gene
expression data obtained in time course (42, 48, 54 h) from the BE(2)-C and IMR-32
cell systems transfected with negative control siRNA or two different HDAC11-
specific siRNAs
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mitotic cell cycle, mitotic cell cycle, cell cycle, cell division,
protein transport and small GTPase-mediated signal trans-
duction. Finding four biological function terms related to cell
cycle and mitosis in the unbiased analysis of expression in
time course from both cell lines coupled with our detecting
cells accumulating in mitosis then undergoing apoptosis
following HDAC11 depletion prompted us to focus on genes
related to the terms, cell cycle and mitosis. In total, 21 and 20
genes representing these terms were regulated in BE(2)-C
and IMR-32 cells, respectively (Figure 3), with 10 genes
being regulated in both cell lines (Figures 3,4a). Down-
regulation was confirmed for 9 (CCNE1, CENPA, CENPE,
DLGAP5, KIF14, KIF23,MAD2L1, RACGAP1 and UHRF1) of
the 10 genes using qRT-PCR (Figure 4b, exemplarily shown
for 48 h). Taken together, the HDAC11 depletion phenotype
characterized by cell accumulation in mitosis and aberrant
spindle assembly formation is associated with downregula-
tion of genes required for mitotic cell cycle progression in
neuroblastoma cells.
We next turned to two independently existing whole-
genome expression profiles from 47630 and 886 primary
neuroblastomas to investigate the correlation between overall
and event-free survival in patients with tumors expressing
CCNE1, CENPA, CENPE, DLGAP5, KIF14, KIF23, MAD2L1,
RACGAP1 or UHRF1. High-level expression of each single
gene strongly correlated with unfavorable overall and event-
free patient survival in the entire cohort and in the patient
subgroup with tumors lacking MYCN amplifications (Table 1;
Supplementary Table S3). No major differences in the
expression of these genes were observed in the patient
subgroup with tumors harboring MYCN amplifications (data
not shown). High-level expression of each single gene also
strongly correlated with the expression of each of the other
seven genes except CCNE1, supporting the concept of a
functionally linked gene group and suggesting a similar
pattern of regulation (Supplementary Figure S5, exemplarily
shown for the Oberthuer cohort30). We also assessed
expression of the nine genes in high-risk neuroblastomas
(as defined by INRG staging31) with (n=67) and without
(n=77) MYCN amplifications in the Kocak tumor cohort.30
High-level expression of the 9-gene group was correlated
(P= 2.08e− 08) withMYCN amplification. Neuroblastomas with
Figure 4 Expression of a group of genes related to the cell cycle and cell division following HDAC11 depletion in neuroblastoma cells. (a) Time course of mRNA expression of
differentially regulated genes associated with the GO terms M-phase of mitotic cell cycle, mitotic cell cycle, cell cycle or cell division. BE(2)-C and IMR-32 cells were transfected
with negative control siRNA or two different HDAC11-specific siRNAs for whole-genome expression analysis (42, 48, 54 h, n= 2) Mean fold change over negative control siRNA
is shown. (b) Validation experiments using qRT-PCR are shown for the 48 h time point (mean fold change over negative control siRNA±S.D., n⩾ 3). *Po0.05; **P⩽ 0.01
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unfavorable biology and associated dismal patient outcome
strongly express this 9-gene group associated with cell cycle
progression.
Counteracting RACGAP1 downregulation partially
rescues caspase 3 induction by HDAC11 depletion. We
aimed to test whether enforced expression of one of the
9-gene group downregulated by HDAC11 depletion should
partially rescue the cell death phenotype. Both a medium-
throughput CellTiter-Glo assay measuring ATP content and
a medium-throughput CaspGlo assay were performed in
BE(2)-C and IMR-32 cells after depletion of each of the nine
genes to identify the most suitable for the rescue experiment.
RNAi targeting the nine genes, each with two different
siRNAs, reduced ATP content in BE(2)-C cells by at least
40% and up to 95% 96 h after transfection (Figure 5a). ATP
content in IMR-32 cells was diminished by at least 55% and
up to 95% after knockdown of CCNE1, CENPA, CENPE,
KIF14, KIF23 or RACGAP1, whereas targeting DLGAP5,
MAD2L1 or UHRF1 did not largely shift ATP content
(Figure 5b). Caspase 3-like induction was assessed in cells
72 h after knockdown of those genes which significantly
influenced cellular ATP in both cell lines. In BE(2)-C cells,
KIF14 or RACGAP1 knockdown caused a 4.5- to 7.7-fold
induction of caspase 3-like activity (Figure 5c). In IMR-32
cells, caspase 3-like activity was triggered 6.5- to 18.2-fold by
siRNA-mediated knockdown of CENPE, KIF23 or RACGAP1
(Figure 5d), and RACGAP1 was identified as the most
suitable gene for rescue experiments. Plasmid-mediated,
enforced RACGAP1 expression to counteract RACGAP1
downregulation by HDAC11 depletion (Supplementary
Figures 6a–c) significantly reduced (Po0.01) induction of
caspase 3-like activity, decreased the number of membrane-
permeable dead BE(2)-C cells and enhanced the number of
viable BE(2)-C cells compared to HDAC11-depleted BE(2)-C
cells transfected with the LacZ expression plasmid
(Figures 5e–g), demonstrating the involvement of RACGAP1
downregulation in the HDAC11 depletion phenotype.
Discussion
Our studies unravel a critical role for HDAC11 in cell cycle
progression and viability of MYCN-amplified neuroblastoma
cells. We recently reported that HDAC11 transcript levels are
significantly higher in several carcinoma entities than corre-
sponding healthy tissues.26 HDAC11 depletion was sufficient
to inhibit metabolic activity and induce cell death in carcinoma
cell lines while having no detectable effects on two different
normal cell types, making HDAC11-inhibiting drugs highly
interesting for programs searching for new targeted therapeu-
tics to treat breast, colon, ovary and prostate cancers.26 These
results suggest tumor selectivity and a relatively broad
therapeutic window, which is important for the future develop-
ment of small molecules selectively inhibiting HDAC11. Here
we deepen the understanding of HDAC11 function in
neuroblastoma. Broad-spectrum HDAC inhibitors have differ-
ent effects on the cell cycle of transformed cells, including cell
cycle arrests in both G1 and G2/M.32 As transformed cells
frequently lack a functional G2 checkpoint, cancer cells
arrested in G2/M frequently undergo apoptosis.32 Our
observation that HDAC11-depleted neuroblastoma cells
accumulate in G2/M, form aberrant spindle assemblies and
subsequently undergo apoptosis suggest the effect elicited by
Table 1 Correlation of mRNA expression of HDAC11-regulated genes with patient outcome in the 476 neuroblastoma cohort by Oberthuer et al.30
Overall survival/entire cohort Event-free survival/entire cohort
Gene Cutoff n (high) n (low) P-valuea Cutoff n (high) n (low) P-valuea
CCNE1 4463.4 80 396 8.4 E− 22 4416.3 82 394 1.7 E− 13
CENPA 1239.5 136 340 5.0 E− 24 1146.9 146 330 4.2 E−22
CENPE 2518.9 133 343 2.0 E− 22 2258.1 155 321 1.7 E− 21
DLGAP5 2443.4 142 334 6.8 E−21 2158.5 160 316 2.2 E− 19
KIF14 293.0 169 307 1.3 E−15 293.0 169 307 5.2 E− 14
KIF23 4447.3 93 383 8.3 E−14 4447.3 93 383 4.4 E− 12
MAD2L1 6671.7 163 313 1.5 E− 22 6671.7 163 313 1.0 E−20
RACGAP1 12864.4 63 413 2.0 E− 09 12949.5 61 415 1.2 E−11
UHRF1 2461.8 151 325 2.1 E− 27 2211.7 171 305 8.1 E−20
Overall survival/MYCN single-copy tumors Event-free survival/MYCN single-copy tumors
Gene Cutoff n (high) n (low) P-valuea Cutoff n (high) n (low) P-valuea
CCNE1 4463.4 40 365 2.5 E−07 4815.1 28 377 1.4 E− 06
CENPA 1671.9 51 354 9.3 E−11 1146.9 87 318 1.7 E− 13
CENPE 2645.6 73 332 1.1 E−11 2258.1 97 308 8.0 E−16
DLGAP5 2158.5 104 301 7.9 E− 11 2158.5 104 301 4.7 E−13
KIF14 617.3 23 382 4.2 E− 09 293.0 118 287 3.4 E−06
KIF23 4447.3 58 347 3.4 E−06 2949.5 138 267 2.7 E−07
MAD2L1 6898.8 97 308 8.7 E−14 6696.5 100 305 9.5 E−15
RACGAP1 15662.4 17 388 1.4 E−07 12949.5 45 360 5.1 E− 08
UHRF1 2461.8 92 313 1.7 E− 15 2023.2 129 276 2.8 E− 14
P-values were adjusted for multiple testing due to cut-point search according to Lausen84
aHigher gene expression was always associated with worse prognosis
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pan-HDAC inhibition is at least in part mediated by targeting
HDAC11.
On a molecular level, downregulation of a 9-gene group
required for proper mitotic cell cycle progression was
observed in an unbiased transcriptome-wide approach.
Knockdown of these genes (CCNE1, CENPA, CENPE,
DLGAP5, KIF14, KIF23, MAD2L1, RACGAP1 and UHRF1)
by siRNAs recapitulated the HDAC11 depletion phenotype,
underlining their importance for mitosis. Counteracting down-
regulation of one of these genes,RACGAP1, partially rescued
the programmed cell death phenotype observed. This
supports the functional relevance of RACGAP1 downregula-
tion for the HDAC11 depletion phenotype. High-level mRNA
expression of the nine genes correlated with unfavorable
patient survival in two independent neuroblastoma cohorts as
well as with MYCN amplification in primary high-risk neuro-
blastomas. Targeting rapid proliferation in MYCN-amplified
neuroblastoma cells by downregulating genes indispensable
for cell cycle progression has previously been shown to elicit
cell cycle arrest and cell death, and is considered a promising
strategy to block the oncogenic effect of MYCN amplification
on cell cycle.33 The strong phenotype produced by HDAC11
depletion in MYCN-amplified neuroblastoma cell lines sup-
ports this approach.
A review of the literature solidifies the importance of the nine
genes downregulated by HDAC11 depletion for proper cell
cycle progression and division, but also reveals associations
with other hallmarks of cancer. Enforced MYCN expression in
SH-EP cells triggers transcriptional activation of cyclin E1
(CCNE1), and high-level CCNE1 expression correlates with
MYCN amplification in primary neuroblastomas.34 Ubiquitin
like with PHD and ring finger domains 1 (UHRF1) encodes a
member of a subfamily of RING finger type E3 ubiquitin ligases
that is required for inheriting methylation during S-phase.35
Centromere protein A (CENPA) is a histone H3 variant that
epigenetically marks where a centromere will form, and
creates a unique more open nucleosome structure allowing
recruitment of CENPC and centrosome establishment.36
In fact, CENPC alone can trigger kinetochore assembly in
defined templates in vitro.37 Although CENPA and CENPC are
parts of the inner kinetochore,38,39 centromere protein E
(CENPE) is a kinesin-like motor protein strongly expressed in
G2 and essential for chromosome alignment by connecting
the outer kinetochore to the spindle microtubule.40 Several
studies have established that CENPE knockdown causes G2
blockade, although cell fate following the G2 block appears to
rely on other genes expressed in the cell.41 Serial transcrip-
tomic analyses of pre-neoplastic ganglia and end-stage
tumors in the TH-MYCN transgenic mouse model iden-
tified increased CENPE expression during tumor progression,
and targeting CENPE with the GSK923295 small-molecule
inhibitor reduced proliferation in human neuroblastoma
cell lines and tumor growth in three xenograft models.42
DLG-associated protein 5 (DLGAP5) is part of a multi-
Figure 5 Enforced RACGAP1 expression partially rescues apoptosis triggered by HDAC11 depletion. (a and b) Intracellular ATP content of BE(2)-C (a) and IMR-32 cultures
(b) 96 h after transfection with candidate gene-specific or negative control siRNAs (mean fold change over mock-transfected cells± S.D. is shown, n= 3). (c and d) Caspase
3-like activity of BE(2)-C (c) and IMR-32 cultures (d) 72 h after transfection with candidate gene-specific or negative control siRNAs (mean fold changes over mock±S.D., n= 3).
(e–g) Caspase 3-like activity (e), dead cell count (f) and viable cell count (g) of BE(2)-C cells 72 h after transfection with HDAC11-specific or negative control siRNAs and 48 h
after transfection of the RACGAP1 plasmid or respective LacZ control (mean fold changes over mock±S.D., n= 3). *Po0.05; **P⩽ 0.01; ***P⩽ 0.001
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component complex and associates with microtubules, thus,
mediating stabilization.43 Kinesin family member 14 (KIF14)
encodes amember of the kinesin-3 superfamily of microtubule
motor proteins that acts to bundle and stabilize midbody
microtubules during cytokinesis.44KIF14 acts as an oncogene
in many cancer entities, including esophageal squamous cell
carcinoma,45 cervical and ovarian cancers,46,47 gliomas,48
retinoblastoma,49,50 glioblastoma,51 hepatocellular
carcinoma,52 lung adenocarcinoma,53 laryngeal
carcinoma,54 synovial carcinomas55 and papillary renal cell
tumors.56 KIF14 is present in the minimal region of chromo-
some 1q gain in breast cancer cell lines, is overexpressed in
breast cancers and its expression positively correlates with
tumor aggressiveness.57,58 KIF14 not only drives cell pro-
liferation, but has been shown to promote chemoresistance via
AKT signaling in triple-negative breast cancer59 and enhance
metastatic and invasive capacity during breast cancer
progression via RAP1A-RADIL signaling inhibition.60 KIF14
is also a key gene necessary for perineural invasion by
pancreatic carcinoma.61 High-level KIF14 expression has also
been reported in cell lines derived from medulloblastomas.62
Together with the results we report here, these data show that
KIF14 hyperactivity resulting from direct genomic gain or gene
upregulation via epigenetic or other mechanisms is asso-
ciated with the most aggressive subgroups of not only adult
cancers but most pediatric embryonal tumors. It is interesting
to note that KIF14 expression is associated with the more
aggressive tumor types of all carcinoma types reported to be
sensitive to HDAC11 inhibition.26 The MAD2 mitotic arrest
deficient-like 1 protein (MAD2L1) is a component of the mitotic
spindle assembly checkpoint that delays anaphase onset until
all chromosomes are properly aligned at the metaphase
plate.63 KIF23 is part of the 157-gene signature for MYCN
activity identified by shRNA-mediated MYCN silencing in
neuroblastoma cells and confirmed by expression studies in
88 neuroblastomas.64 KIF23 and Rac GTPase activating
protein 1 (RACGAP1) are highly expressed during G2/M.65,66
RACGAP1 and KIF23 form the centralspindlin complex,67 a
motor complex essential for virtually every step in cytokinesis
including mitotic spindle formation and anchoring. Absence of
either protein leads to failure of cytokinesis due to deficient
central spindle assembly and contractile ring formation.68 The
aberrant spindle assembly formation we observed in
HDAC11-depleted neuroblastoma cells suggests that
HDAC11 disrupts the complex machinery regulating these
processes, likely via KIF23, MAD2L1 and RACGAP1. High-
level RACGAP1 expression was also observed in different
cancer entities.69–72 The nine genes we show downregulated
by HDAC11 depletion in G2/M-arrested neuroblastoma cells
all play an important role in proper cell cycle progression and
division, but some are also key players in cancer hallmarks
associated with progression to more aggressive tumor
phenotypes, including development of chemoresistance,
metastases and invasive potential. HDAC11 may provide a
druggable regulatory node to reduce many functions neces-
sary for developing aggressiveness in multiple cancers
affecting adults and children.
Our previous investigations unraveled specific and non-
redundant oncogenic functions of HDAC2/3/5/8/10 in neuro-
blastoma pathophysiology.19,20,23,73,74 The clinical application
of pan-HDAC inhibitors showed dose-limiting toxicities, which
is not surprising considering the central role of HDACs in
modulating chromatin structure and cytoplasmic processes
such as autophagy. Selective inhibitors may improve anti-
tumoral efficacy, and have already been successfully devel-
oped against single HDACs. HDAC11-selective inhibitors
have as yet not been developed. Here we show that HDAC11
depletion in MYCN-amplified neuroblastoma cells triggers
programmed cell death preceded by an accumulation of
mitotic cells characterized by aberrant spindle assembly
formation. On a molecular level, downregulation of a 9-gene
group required for proper mitotic cell cycle progression was
observed in an unbiased transcriptome-wide approach, and
counteracting RACGAP1 downregulation by HDAC11 deple-
tion partially rescued the programmed cell death phenotype
observed. The 9-gene group includes KIF14, a known
oncogene associated with aggressive tumor qualities in many
cancers, linking HDAC11 epigenetic regulation to the hall-
marks of aggressive cancers. Taken together, our data
illustrate an important role for HDAC11 in cell cycle progres-
sion and viability ofMYCN-amplified neuroblastoma cells, and
illuminates HDAC11 as a potential novel drug target for this
subgroup of high-risk neuroblastomas.
Materials and Methods
Cell culture and chemicals. The BE(2)-C and SK-N-AS neuroblastoma cell
lines were obtained from ECACC (Salisbury, UK), and the IMR-32 and SH-SY5Y
cell lines from the DSMZ (Braunschweig, Germany). Cell lines were monitored for
infections by high-throughput multiplex cell contamination testing.75 Cell line
authenticity was validated by high-throughput SNP-based assays.76 BE(2)-C, SK-N-
AS, IMR-32 and SK-N-AS cell lines were cultured in DMEM (Lonza, Basel,
Switzerland) supplemented with 10% FCS (Sigma-Aldrich, Hamburg, Germany) and
1% non-essential amino acids (NEAA; Lonza) at 37°C and 5% CO2. The broad
range caspase inhibitor, zVAD.fmk (Bachem, Heidelberg, Germany), was directly
added to the cell culture medium to obtain a final concentration of 20 μM, whereas
controls were treated with DMSO.
Microscopy. Living native cells were examined with an inverted widefield
microscope (Olympus CKX41, Tokyo, Japan). Software Cell^B (Olympus) was used
for the acquisition of microscopic images. Fixed, DAPI-labeled cells were viewed
under both the Olympus CKX41 and a laser-scanning confocal microscope (Zeiss
LSM700, Oberkochen, Germany) equipped with the ZEN 2012 blue edition software
(Zeiss). Operators performing the quantification of DAPI-labeled mitotic cells were
blinded to the treatment group. Positive cells were counted using the Cell^B
software (Olympus) counting tool.
Transfection of siRNAs and DNA plasmids. For knockdown experi-
ments, cells were transiently transfected with 25 nM siRNA (Supplementary
Table S1) using the HiPerFect method (Qiagen, Hilden, Germany) according to the
manufacturer’s directions. For plasmid transfection, the Effectene method
(Qiagen) was used according to the manufacturer’s manual. Applying the
GATEWAY technology (Invitrogen, Carlsbad, CA, USA), the RACGAP1 comple-
mentary DNA (cDNA) sequence (EU176264) was cloned from the pENTR221
vector into the destination vector pT-REx-DEST30. The empty pT-REx-DEST30
vector and the LacZ expression vector, pT-REx/GW30/LacZ (Invitrogen), served as
controls. For the expression of Myc-tagged HDAC11, the MYC tag sequence
(MEQKLISEEDL) was N-terminally inserted into the expression vector pcDNA3.1
carrying the wild-type HDAC11 sequence.19 The correct sequences of all inserts
were verified by DNA sequencing (GATC, Konstanz, Germany).
RNA extraction, cDNA synthesis and qRT-PCR. Total RNA was
isolated from BE(2)-C and IMR-32 cell lines using the RNeasy Mini Kit (Qiagen).
The Thermo Scientific First-Strand cDNA Synthesis Kit (Thermo Scientific,
Waltham, MA, USA) was used to transcribe cDNAs for qRT-PCR analysis. Relative
gene expression was measured using SYBR Green Dye (Eurogentec, Cologne,
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Germany) on an ABI Prism 7500 thermal cycler (Perkin-Elmer Applied Biosystems,
Weiterstadt, Germany). All primers used in qRT-PCR are listed in the
Supplementary Table S2. Data were analyzed using Applied Biosystems 7500
software v2.0.5 (Thermo Scientific), and changes in gene expression were
calculated using the ΔΔCt method.
Western blotting. Western blots were performed as described19,77 using the
following antibodies: mouse monoclonal anti-β-actin (clone AC-15, Sigma-Aldrich,
St. Louis, MO, USA), rabbit polyclonal anti-CASP3 (Cell Signaling, Danvers, MA,
USA), mouse monoclonal anti-GAPDH (clone 6C5; Merck Millipore, Darmstadt,
Germany), mouse monoclonal anti-HDAC1 (clone 10E2; Abcam, Cambridge, UK),
mouse monoclonal anti-HDAC2 (clone 3F3; Abcam), rabbit polyclonal anti-HDAC3
(clone H-99; Santa Cruz Biotechnology, Dallas, TX, USA), rabbit polyclonal
anti-HDAC8 (Abcam), mouse monoclonal anti-MYC tag (GeneTex, Irvine, CA, USA),
mouse monoclonal anti-PARP (Cell Signaling), mouse monoclonal anti-phospho H3
(Ser10) (Cell Signaling), rabbit monoclonal anti-histone H3 (Cell Signaling) and
rabbit polyclonal anti-RACGAP1 (Santa Cruz Biotechnology). Band density was
analyzed using ImageJ 1.47p software (Wayne Rasband, National Institute of
Health, Bethesda, MD, USA) on western blots, and results were normalized to the
respective loading controls.
Trypan blue exclusion and CellTiter-Glo assays. Cell number and
viability were semi-automatically measured with the VI-CELL Cell Viability Analyzer
(Beckman, Krefeld, Germany) based on the trypan blue exclusion method.20 The
CellTiter-Glo luminescent cell viability assay (Promega, Fitchburg, WI, USA) was
used according to the manufacturer’s directions to measure the amount of
intracellular ATP.
Flow cytometry. Cell cycle distribution and DNA fragmentation was
determined on a FACS Calibur flow cytometer (BD Biosciences, Heidelberg,
Germany) using the CellQuest Pro software (BD Biosciences) after cell nuclei were
stained with propidium iodide.19 The FITC Annexin V Apoptosis Detection Kit I
(BD Pharmingen, Heidelberg, Germany) was used to quantify phosphatidylserine at
the outer cell membrane.
Caspase activity assay. Cells were seeded, treated as indicated, collected
with supernatant and lysed in cell lysis buffer (Biovision, Mountain View, CA, USA)
for 10 min on ice. Protein concentrations were normalized using the Pierce assay.
Thereafter, reaction buffer (MBL International, Woburn, MA, USA) and AFC-labeled
caspase 3-specific peptide, DEVD (Biomol, Hamburg, Germany), were added.
Caspase 3-like activity was measured at 37 °C in black 96-well plates using a
fluorescence plate reader with a 380 nm excitation filter and a 530 nm emission
filter.19 The Caspase Glo 3/7 assay (Promega) facilitating direct measurements
without cell harvest and lysis was used for medium-throughput analyses, and results
were normalized to the amount of intracellular ATP measured by the CellTiter-
Glo assay.
Probe labeling, Illumina Sentrix BeadChip array hybridization
and microarray scanning. RNA isolated from cell lines as described above
was resuspended in TE buffer and eluted in water. Quality of total RNA was checked
by gel analysis using the total RNA NanoChip Assay on an Agilent 2100
Bioanalyzer (Agilent Technologies GmbH, Berlin, Germany). Samples with RNA
indices 48.5 were selected for expression profiling. RNA concentrations were
determined with a NanoDrop spectrophotometer (NanoDrop Technologies,
Wilmington, DE, USA). Biotin-labeled cRNA samples were prepared for
hybridization on Illumina Human Sentrix-12 BeadChip arrays (Illumina Inc., San
Diego, CA, USA) according to the sample labeling procedure recommended by
Illumina with minor modifications.78 In brief, 250 ng total RNA was used for cDNA
synthesis, followed by an amplification and labeling step to synthesize biotin-labeled
cRNA according to the Illumina TotalPrep RNA Amplification Kit (Life Technologies,
Carlsbad, CA, USA). The cRNA was column-purified with the TotalPrep RNA
Amplification Kit and eluted in 60 μl of water. The cRNA quality was controlled with
the RNA NanoChip Assay on an Agilent 2100 Bioanalyzer, and the cRNA content
was spectrophotometrically quantified with a NanoDrop.
Hybridization was performed at 58°C in GEX-HCB buffer (Illumina Inc.) at a
concentration of 100 ng cRNA/μl, unsealed in a wet chamber for 20 h. Thereafter,
mismatch control oligonucleotides, biotinylation control oligonucleotides and spike-in
controls for low-, medium- and highly abundant RNAs were added. Microarrays were
washed once in High Temp Wash buffer (Illumina Inc.) at 55°C and twice in E1BC
buffer (Illumina Inc.) at room temperature for 5 min. In between, microarrays were
washed with ethanol at room temperature. After blocking for 5 min in 4 ml of 1% (w/v)
Blocker Casein in phosphate-buffered saline Hammarsten grade (Pierce Biotechnol-
ogy Inc., Rockford, IL, USA), array signals were developed by a 10 min incubation in
2 ml of 1 μg/ml Cy3-streptavidin solution (Amersham Biosciences, Buckinghamshire,
UK) and 1% blocking solution. After a final wash in E1BC, microarrays were dried and
scanned using an iScan array scanner. Data extraction was done for all beads
individually. Outliers, identified as having 42.5 MAD (median absolute deviation),
were removed. All remaining data points were used for the calculation of the mean
average signal and S.D. for a given probe. The data discussed in this publication have
been deposited in NCBI's Gene Expression Omnibus79 and are accessible through
GEO Series accession number GSE77080 (http://www.ncbi.nlm.nih.gov/geo/query/
acc.cgi?acc=GSE77080).
Statistical analysis. Microarray data obtained in duplicates were normalized
using quantile normalization in the 'R programming language'. Quantile-normalized
Illumina mRNA data were log2 transformed. Differentially expressed transcripts were
identified for each HDAC11 siRNA separately in comparison to the negative control
transfection using the empirical Bayes approach as implemented in the
Bioconductor package limma.80 Time points were tested globally using moderated
F-statistics and individually using moderated t-statistics, both based on the same
linear model. All P-values were adjusted for multiple testing using the Benjamini–
Hochberg correction.81 Next, transcripts that showed a significant regulation at two
or more time points in the same direction and no significant regulation in the
opposite direction, were selected. The overlap of these selected transcripts from
both siRNAs defined the primary list of regulated transcripts (hits). This analysis
was performed separately for each cell line. GO terms were analyzed for over-
representation and enrichment. First, hypergeometric tests were used to test for
over-representation of GO terms within the hit list. Second, a gene set enrichment
analysis was performed using the minimal F-statistics from both siRNA models as a
global measurement of regulation. Taking the minimal moderated F-statistic value
from both linear models can be considered a conservative approach because the
lesser strength of regulation from both siRNAs is selected to represent the
transcript, thus mimicking the requirement to show regulation in both siRNAs. In
case multiple transcripts mapped to the same Entrez Gene ID, duplicates were
removed for both analyses by using only the transcript that showed the strongest
regulation to represent the gene. Again, P-values were adjusted for multiple testing
using Benjamini–Hochberg correction.81 GO analyses were carried out for each cell
line separately with the Bioconductor package HTSanalyzeR.82 GO terms showing
both a significant over-representation and enrichment were selected for further
investigation. All analyses were carried out using R,83 and all tests were two-sided.
Effects of HDAC11 depletion on phenotype compared to those of negative control
siRNA transfection were analyzed by a mixed linear model with a fixed effect for
HDAC11-depleted samples in comparison to negative control treated cultures and
random intercept for each individual HDAC11 or negative control siRNA using SAS
PROC MIXED, SAS Version 9.2 (SAS Institute Inc., Cary, NC, USA). Comparison of
qRT-PCR data was performed with a paired two-tailed t-test (GraphPad Prism version
5.01, GraphPad Software, Inc., La Jolla, CA, USA). P-values below 0.05 were
considered statistically significant.
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